Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS Hears Earful From Supporters Of Cochlear Coverage Criteria Expansion

This article was originally published in The Gray Sheet

Executive Summary

Advanced Bionics recommends that CMS tie coverage criteria for cochlear implants to FDA indications as an alternative to establishing specific cutoff criteria

You may also be interested in...



Medicare To Expand Cochlear Coverage, Stops Short Of Requested Scope

CMS is willing to expand cochlear implant coverage for Medicare beneficiaries, but undershoots Cochlear Americas' full coverage request

Medicare To Expand Cochlear Coverage, Stops Short Of Requested Scope

CMS is willing to expand cochlear implant coverage for Medicare beneficiaries, but undershoots Cochlear Americas' full coverage request

Cochlear implant coverage

CMS accepts Cochlear Corp. (Nucleus 24 contour implant system) request July 8 for consideration of expanded cochlear implant national coverage based on the firm's expanded labeling, granted by FDA in 2000. FDA allows implantation in patients with test scores of 50% or less, but CMS currently permits coverage for patients with demonstrated test scores of 30% or less. CMS requests that the public submit medical evidence and published literature detailing expanded use of cochlear implants in adults and children, patient selection criteria and the appropriate screening needed to qualify a patient for an implant. The agency expects to issue a decision by April 4, 2005...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT020898

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel